Hemophilia Care in the Pediatric Age
- PMID: 28534860
- PMCID: PMC5447945
- DOI: 10.3390/jcm6050054
Hemophilia Care in the Pediatric Age
Abstract
Hemophilia is the most common of the severe bleeding disorders and if not properly managed since early infancy can lead to chronic disease and lifelong disabilities. However, it enjoys the most efficacious and safe treatment among the most prevalent monogenic disorders. Hemophilia should be considered in the neonatal period in the case of unusual bleeding or in the case of positive family history. Later, hemophilia should be suspected mainly in males because of abnormal bruising/bleeding or unusual bleeding following invasive procedures-for example, tonsillectomy or circumcision. Prophylactic treatment that is started early with clotting-factor concentrates has been shown to prevent hemophilic arthropathy and is, therefore, the gold standard of care for hemophilia A and B in most countries with adequate resources. Central venous access catheters and arterovenous fistulas play an important role in the management of hemophilia children requiring repeated and/or urgent administration of coagulation factor concentrates. During childhood and adolescence, personalized treatment strategies that suit the patient and his lifestyle are essential to ensure optimal outcomes. Physical activity is important and can contribute to better coordination, endurance, flexibility and strength. The present article focuses also on questions frequently posed to pediatric hematologists like vaccinations, day-care/school access and dental care.
Keywords: child; hemophilia; neonate; prophylaxis; psychology; sport; treatment; vaccinations; venous access.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Pavlovsky A. Contribution to the pathogenesis of hemophilia. Blood. 1947;2:185–191. - PubMed
-
- White G.C., Rosendaal F., Aledort L.M., Lusher J.M., Rothschild C., Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 2001;85:560. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
